Long-Term Outcome of Esthesioneuroblastoma: Hyams Grade Predicts Patient Survival

Abstract

Object Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine tumor originating from the olfactory neuroepithelium in the cribriform plate. Controversy still exists regarding the role of pathologic grading (Hyams grade) in prognostication. This study was undertaken to describe our experience with ENB and assess the role of pathologic grading in patient outcome.

Methods This was a retrospective, single-institution experience, including 109 patients with ENB treated at our institution from 1962 to 2009. Multivariate analysis was performed utilizing Cox regression analysis models utilizing age, gender, modified Kadish stage, and Hyams grade.

Results Mean age was 49 ± 16 (median 50) years at presentation (range 12 to 90 years). Median follow up was 5.1 years. All-cause mortality was significantly influenced by Hyams grading in univariate (p = 0.04) and multivariate (p = 0.02) analysis, in addition to proven prognostic factors, Kadish staging, lymph node metastasis, and age. Median survival was 9.8 years compared with 6.9 years with low (grade 1 to 2) versus high (grade 3 to 4) Hyams grade. Median overall survival was 7.2 ± 0.7 years.

Conclusion ENB has a variable outcome, which is primarily prognosticated by the extent of involvement at presentation (Kadish stage and lymph node metastasis) and higher Hyams pathologic grade.

Keywords

esthesioneuroblastoma - olfactory neuroblastoma - outcome - Hyams grade - surgical treatment

• References

• 1 Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003; 123: 433-439
• 2 Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001; 2: 683-690
• 3 Elkon D, Hightower SI, Lim ML, Cantrell RW, Constable WC. Esthesioneuroblastoma. Cancer 1979; 44: 1087-1094
• 4 Kane AJ, Sughrue ME, Rutkowski MJ , et al. Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg 2010; 113: 340-351
• 5 Samant SHE, Pfister D, Hanna E , et al. Preoperative high-dose radiotherapy and conmittant cisplatin chemotherapy followed by surgery for advanced paranasal sinus carcinoma. Available at: https://wwwnasbsorg/documents/NASBS_PNS100405_protocolpdf ; 2006
• 6 Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133: 276-280
• 7 Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32: 706-714 , discussion 714–715
• 8 Loy AH, Reibel JF, Read PW , et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 2006; 132: 134-138
• 9 Chao KS, Kaplan C, Simpson JR , et al. Esthesioneuroblastoma: the impact of treatment modality. Head Neck 2001; 23: 749-757
• 10 Berger L, Luc G, Richard D. L'Esthesioneuroepitheliome Olfactif. Bull Assoc Fr Etud Cancer 1924; 13: 410-421
• 11 Dias FL, Sa GM, Lima RA , et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003; 129: 1186-1192
• 12 Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 1992; 102: 843-849
• 13 Homzie MJ, Elkon D. Olfactory esthesioneuroblastoma—variables predictive of tumor control and recurrence. Cancer 1980; 46: 2509-2513
• 14 Hwang S-K, Paek S-H, Kim DG, Jeon YK, Chi JG, Jung HW. Olfactory neuroblastomas: survival rate and prognostic factor. J Neurooncol 2002; 59: 217-226
• 15 Ingeholm P, Theilgaard SA, Buchwald C, Hansen HS, Francis D. Esthesioneuroblastoma: a Danish clinicopathological study of 40 consecutive cases. APMIS 2002; 110: 639-645
• 16 Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37: 1571-1576
• 17 Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future?. Laryngoscope 2003; 113: 502-507
• 18 McCaffrey TV, Olsen KD, Yohanan JM, Lewis JE, Ebersold MJ, Piepgras DG. Factors affecting survival of patients with tumors of the anterior skull base. Laryngoscope 1994; 104: 940-945
• 19 Miyamoto RC, Gleich LL, Biddinger PW, Gluckman JL. Esthesioneuroblastoma and sinonasal undifferentiated carcinoma: impact of histological grading and clinical staging on survival and prognosis. Laryngoscope 2000; 110: 1262-1265
• 20 Ong YK, Solares CA, Carrau RL, Snyderman CH. New developments in transnasal endoscopic surgery for malignancies of the sinonasal tract and adjacent skull base. Curr Opin Otolaryngol Head Neck Surg 2010; 18: 107-113
• 21 Ozsahin M, Gruber G, Olszyk O , et al. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys 2010; 78: 992-997
• 22 VJ H. Tumors of the upper respiratory tract and ear. Washington DC: Armed Forces Institute of Pathology; 1988
• 23 Zimmer LA, Theodosopoulos PV. Anterior skull base surgery: open versus endoscopic. Curr Opin Otolaryngol Head Neck Surg 2009; 17: 75-78
• 24 Foote RL, Morita A, Ebersold MJ , et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27: 835-842
• 25 Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope 1990; 100: 1199-1201
• 26 Unger F, Haselsberger K, Walch C, Stammberger H, Papaefthymiou G. Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma). Acta Neurochir (Wien) 2005; 147: 595-601 , discussion 601–602
• 27 Unger F, Walch C, Stammberger H, Papaefthymiou G, Haselsberger K, Pendl G. Olfactory neuroblastoma (esthesioneuroblastoma): report of six cases treated by a novel combination of endoscopic surgery and radiosurgery. Minim Invasive Neurosurg 2001; 44: 79-84